BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29584739)

  • 1. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
    Chudecka-Głaz A; Cymbaluk-Płoska A; Wężowska M; Menkiszak J
    PLoS One; 2018; 13(3):e0194270. PubMed ID: 29584739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.
    Skaznik-Wikiel ME; Sukumvanich P; Beriwal S; Zorn KK; Kelley JL; Richard SD; Krivak TC
    Int J Gynecol Cancer; 2011 Aug; 21(6):1013-7. PubMed ID: 21792011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.
    Chudecka-Głaz AM; Cymbaluk-Płoska AA; Menkiszak JL; Sompolska-Rzechuła AM; Tołoczko-Grabarek AI; Rzepka-Górska IA
    J Ovarian Res; 2014; 7():62. PubMed ID: 25018782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    Eur J Surg Oncol; 2019 Apr; 45(4):644-649. PubMed ID: 30337203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Petzold M; Jakobsen A
    Int J Gynecol Cancer; 2012 Nov; 22(9):1474-82. PubMed ID: 23095772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.
    Kong SY; Han MH; Yoo HJ; Hwang JH; Lim MC; Seo SS; Yoo CW; Kim JH; Park SY; Kang S
    Ann Surg Oncol; 2012 May; 19(5):1707-12. PubMed ID: 21833668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
    Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
    Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer.
    Aarenstrup Karlsen M; Høgdall C; Nedergaard L; Philipsen Prahm K; Schou Karlsen NM; Weng Ekmann-Gade A; Henrichsen Schnack T; Svenstrup Poulsen T; Jarle Christensen I; Høgdall E
    APMIS; 2016 Dec; 124(12):1038-1045. PubMed ID: 27859687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer.
    Rong Y; Li L
    J Ovarian Res; 2021 Jan; 14(1):2. PubMed ID: 33397458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
    Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
    Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of serum HE4 levels and risk of ovarian malignancy algorithm scores at the time of ovarian cancer diagnosis.
    Kaijser J; Van Belle V; Van Gorp T; Sayasneh A; Vergote I; Bourne T; Van Calster B; Timmerman D
    Int J Gynecol Cancer; 2014 Sep; 24(7):1173-80. PubMed ID: 24987915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human epididymis protein 4 (HE4) and ovarian cancer prognosis.
    Trudel D; Têtu B; Grégoire J; Plante M; Renaud MC; Bachvarov D; Douville P; Bairati I
    Gynecol Oncol; 2012 Dec; 127(3):511-5. PubMed ID: 22967799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?
    Angioli R; Capriglione S; Aloisi A; Guzzo F; Luvero D; Miranda A; Damiani P; Montera R; Terranova C; Plotti F
    Tumour Biol; 2014 Jul; 35(7):7009-15. PubMed ID: 24748235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.